This is the authors' abstract. We don't add key points for this paper.
1062 Background: Triple negative breast cancers (TNBC) lack expression of ER, PR and HER2. Consequently, targeted therapy is currently unavailable for these patients. At least some TNBCs however, possess high levels of EGFR and are dependent on EGFR signaling. Activation of EGFR signaling is triggered by the release of ligands such as TGFα, EGF and HB-EGF. Release of these ligands is catalysed by the proteases, ADAM10 and ADAM17. The aim of this study was to test the hypothesis that inhibition of ADAM10/17 was a new approach for treating patients with TNBC. Methods: ADAM10 and 17 were measured at protein and mRNA levels in extracts of TN and non-TNBC. Pooled data from 22 published gene expression databases (N=approx 4,000 patients) was used to relate ADAM and ADAM17 mRNA to patient outcome. The effect of the dual ADAM10/17 inhibitor, GW280264X (GSK) on the proliferation of 7 TN and 6 non-TN breast cancer cell lines was investigated using the acid phosphatase assay and Calcusyn software. Results: Using extracts of breast cancer (n=185), the active form of ADAM17 was found in 98 % of TN and 95 % of non-TN samples. Importantly, significantly higher levels were present in TN than non-TN samples (p = 0.025, Mann Whitney U). Similarly, the active form of ADAM10 was detected in the majority (82%) of TN samples. Using pooled data from published datasets, high ADAM10 expression was associated with adverse prognosis in patients with basal-type (most of which were TN) breast cancer. Using the dual ADAM10/17 inhibitor GW280264X, we found up to 90 % reduction in cell growth (36 to 89 % growth reduction) across a panel of TNBC lines with IC50 concentrations ranging from 0.43 µM to 2.8 µM. In contrast, non TNBC lines responded with a range of 10 to 73 % growth inhibition and IC50 concentrations of 2.8 to >20 µM. Conclusions: Our results indicate that ADAM10 and 17 are expressed in the majority of TNBCs. Furthermore, ADAM inhibition resulted in impaired cell growth, migration and invasion of TNBC cells in vitro. Taken together, we propose that ADAM10 and ADAM17 may be novel targets for therapeutic intervention in TNBC. Authors PMcG and MM contributed equally to this work.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mullooly et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: